Core Insights - Illumina Inc. (NASDAQ:ILMN) is collaborating with global pharmaceutical companies to develop companion diagnostics (CDx) for KRAS biomarkers using its TruSight Oncology Comprehensive genomic profiling test [1][2]. Group 1: Collaboration and Development - The collaborations aim to enhance tumor-agnostic CDx claims for KRAS mutations, which are associated with uncontrolled cell growth leading to cancer [2]. - Illumina Inc. is expanding its pipeline of CDx claims to support immunotherapies and targeted medicines through these pharmaceutical agreements [3]. Group 2: Company Overview - Illumina Inc. is a life sciences company that develops and produces tools and systems for genomic research, including sequencing platforms and microarrays for evaluating genetic data [3].